P2X purinoreceptors (P2X receptor)

P2X purinoreceptors are a family of ATP-gated, nonselective cation channels with seven known subtypes (P2X1–P2X7), widely distributed in neuronal, immune, and nonneuronal cells. They form trimeric complexes with each subunit containing two transmembrane domains, a large extracellular loop, and intracellular termini. Physiologically, they mediate rapid signaling by allowing influx of sodium, potassium, and calcium ions in response to extracellular ATP. P2X receptors play roles in neurotransmission, pain, inflammation, cell death, and muscle contraction. They are validated therapeutic targets for conditions including chronic pain, inflammation, neurodegenerative disease, cancer, and cardiovascular disorders, as well as status epilepticus. Several selective antagonists have been developed, some reaching clinical trials, though challenges remain in subtype-selectivity and efficacy. Biomarker development focuses on receptor expression and downstream signaling molecules (e.g., cytokines). Safety concerns are linked to their broad physiological roles and the need for highly specific targeting.

Other names

P2X receptorpurinergic receptor P2XP2X purinoreceptorATP-gated ion channelP2X ion channel

Drugs targeting P2X receptors primarily act as direct antagonists of ATP binding, thereby blocking channel activation. This often involves competitive inhibition at the orthosteric ATP-binding site. Some compounds modulate receptor gating, preventing cation influx. Allosteric inhibition is also observed with certain compounds.